$OVID News

We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Ovid Therapeutics Q1 EPS $(0.12) Misses $(0.11) Estimate

Here is Why Ovid Therapeutics (OVID) is One of the Best Fast Growing Penny Stocks

Wedbush Reiterates Outperform on Ovid Therapeutics, Maintains $7 Price Target

Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders - Slideshow

Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript

Ovid Therapeutics shares are trading higher after HC Wainwright & Co. maintained its Buy rating on the stock and raised its price target from $2 to $4.

Ovid Therapeutics shares are trading higher after HC Wainwright & Co. maintained its Buy rating on the stock and raised its price target from $2 to $4.

HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $4

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

OVID Therapeutics Inc (NASDAQ:OVID) Passes Minervini's High-Growth Momentum and Trend Template Filters

Ovid Therapeutics shares are trading higher after Wedbush mantained its Outperform rating and raises its price target from $5 to $7.

Wedbush Maintains Outperform on Ovid Therapeutics, Raises Price Target to $7

Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding

Ovid Therapeutics Inc. 2025 Q4 - Results - Earnings Call Presentation

Ovid Therapeutics Q4 Earnings Call Highlights

Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally